# Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

> **NCT02476539** · PHASE1 · COMPLETED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 28 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** Hemay022

## Key facts

- **NCT ID:** NCT02476539
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-14
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476539, "Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT02476539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*